Diffuse alveolar hemorrhage in coumarin users: A fibrosing interstitial pneumonia trigger?

Lung

Volumn 191, Issue 1, 2013, Pages 53-59

  Wijnen, Petal A ^a   Verschakelen, Johny A ^b   Bast, Aalt ^c   Bekers, Otto ^a   Drent, Marjolein ^d  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d GELDERSE VALLEI HOSPITAL   (Netherlands)

Author keywords

Anticoagulants; Diffuse alveolar hemorrhage; Fibrosing interstitial pneumonia; Oxidative stress

Indexed keywords

COUMARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIFFUSE ALVEOLAR HEMORRHAGE; DISEASE COURSE; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL PNEUMONIA; LUNG HEMORRHAGE; MALE; MEDICAL RECORD REVIEW; OXIDATIVE STRESS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; COUMARINS; FEMALE; HEMORRHAGE; HUMANS; LUNG DISEASES; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OXIDATIVE STRESS; PULMONARY ALVEOLI; PULMONARY FIBROSIS; RETROSPECTIVE STUDIES; RISK FACTORS; VENOUS THROMBOSIS;

EID: 84873088363     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-012-9436-2     Document Type: Article

References (54)

1. American Thoracic Society/European Respiratory Society (2002) International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165(2):277-304
2. Monaghan H, Wells AU, Colby TV, du Bois RM, Hansell DM, Nicholson AG (2004) Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest 125(2):522-526
3. Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788-824
4. Martinez FJ, Safrin S, Weycker D et al (2005) The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 142(12 Pt 1):963-967
5. Churg A, Muller NL, Silva CI, Wright JL (2007) Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am J Surg Pathol 31(2):277-284
6. Collard HR, Moore BB, Flaherty KR et al (2007) Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176(7):636-643
7. Rahman I, Skwarska E, Henry M, Davis M, O'Connor CM, FitzGerald MX, Greening A, MacNee W (1999) Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis. Free Radic Biol Med 27(1-2):60-68
8. Markart P, Luboeinski T, Korfei M et al (2009) Alveolar oxidative stress is associated with elevated levels of nonenzymatic low-molecular-weight antioxidants in patients with different forms of chronic fibrosing interstitial lung diseases. Antioxid Redox Signal 11(2):227-240
9. Wijnen PA, Linssen CF, Haenen GR, Bekers O, Drent M (2010) Variant VKORC1 and CYP2C9 alleles in patients with diffuse alveolar hemorrhage caused by oral anticoagulants. Mol Diagn Ther 14(1):23-30
10. Balkisson R, Murray D, Hoffstein V (1992) Alveolar damage due to inhalation of amitrole-containing herbicide. Chest 101(4):1174-1176
11. Jinn Y, Akizuki N, Ohkouchi M, Inase N, Ichioka M, Marumo F (1998) Acute lung injury after inhalation of water-proofing spray while smoking a cigarette. Respiration 65(6):486-488
12. Kayser K, Plodziszewska M, Waitr E, Slodkowska J, Altiner M, Gabius HJ (1998) Diffuse pulmonary hemosiderosis after exposure to pesticides. A case report. Respiration 65(3):214-218
13. Spahr JE, Maul JS, Rodgers GM (2007) Superwarfarin poisoning: a report of two cases and review of the literature. Am J Hematol 82(7):656-660
14. Maldonado F, Parambil JG, Yi ES, Decker PA, Ryu JH (2009) Haemosiderin-laden macrophages in the bronchoalveolar lavage fluid of patients with diffuse alveolar damage. Eur Respir J 33(6):1361-1366
15. De Lassence A, Fleury-Feith J, Escudier E, Beaune J, Bernaudin JF, Cordonnier C (1995) Alveolar hemorrhage. Diagnostic criteria and results in 194 immunocompromised hosts. Am J Respir Crit Care Med 151(1):157-163
16. Hwang JH, Misumi S, Sahin H, Brown KK, Newell JD, Lynch DA (2009) Computed tomographic features of idiopathic fibrosing interstitial pneumonia: comparison with pulmonary fibrosis related to collagen vascular disease. J Comput Assist Tomogr 33(3):410-415
17. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC (1993) Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for steel and coal. Official statement of the European Respiratory Society. Eur Respir J Suppl 16:5-140
18. Jacobs JA, De Brauwer E (1999) BAL fluid cytology in the assessment of infectious lung disease. Hosp Med 60(8):550-555
19. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G (2006) Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174(7):810-816
20. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ (2006) Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 61(11):980-985
21. Meltzer EB, Noble PW (2008) Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 3:8
22. Kaarteenaho R, Kinnula VL (2011) Diffuse alveolar damage: a common phenomenon in progressive interstitial lung disorders. Pulm Med 531302:1-10
23. Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, Hubbard RB (2011) The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 66(6):462-467
24. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T (2006) Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 27(1):143-150
25. Song JW, Hong SB, Lim CM, Koh Y, Kim DS (2011) Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 37(2):356-363
26. Hyzy R, Huang S, Myers J, Flaherty K, Martinez F (2007) Acute exacerbation of idiopathic pulmonary fibrosis. Chest 132(5):1652-1658
27. Papiris SA, Manali ED, Kolilekas L, Kagouridis K, Triantafillidou C, Tsangaris I, Roussos C (2010) Clinical review: idiopathic pulmonary fibrosis acute exacerbations - unravelling Ariadne's thread. Crit Care 14(6):246
28. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13):1690-1698
29. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, Sasaki H (2005) Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128(3):1475-1482
30. Brown KK, Wells AU (2008) Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-a study. Eur Respir J 17(109):116-122
31. Kinder BW, Collard HR, King TE Jr (2006) Anticoagulant therapy and idiopathic pulmonary fibrosis. Chest 130(1):302-303
32. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA (2012) A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 186(1):88-95
33. Sconce E, Avery P, Wynne H, Kamali F (2007) Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 109(6):2419-2423
34. Sconce EA, Avery PJ, Wynne HA, Kamali F (2008) Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism influences the anticoagulation response subsequent to vitamin K intake: a pilot study. J Thromb Haemost 6(7):1226-1228
35. Ferland G, Sadowski JA, O'Brien ME (1993) Dietary induced subclinical vitamin K deficiency in normal human subjects. J Clin Investig 91(4):1761-1768
36. Shimada K, Matsuda T, Inamatsu T, Urayama K (1984) Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics. J Antimicrob Chemother 14(Suppl B):325-330
37. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):204S-233S
38. Drent M, Wessels S, Jacobs JA, Thijssen H (2000) Association of diffuse alveolar haemorrhage with acquired vitamin K deficiency. Respiration 67(6):697
39. Rahman I, Biswas SK, Kirkham PA (2006) Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol 72(11):1439-1452
40. Vervoort LM, Ronden JE, Thijssen HH (1997) The potent antioxidant activity of the vitamin K cycle in microsomal lipid peroxidation. Biochem Pharmacol 54(8):871-876
41. Wu J, Chien CC, Yang LY, Huang GC, Cheng MC, Lin CT, Shen SC, Chen YC (2011) Vitamin K3-2, 3-epoxide induction of apoptosis with activation of ROS-dependent ERK and JNK protein phosphorylation in human glioma cells. Chem Biol Interact 193(1):3-11
42. Canfield LM, Davy LA, Thomas GL (1985) Anti-oxidant/pro-oxidant reactions of vitamin K. Biochem Biophys Res Commun 128(1):211-219
43. Tanaka S, Nishiumi S, Nishida M et al (2010) Vitamin K3 attenuates lipopolysaccharide-induced acute lung injury through inhibition of nuclear factor-kappaB activation. Clin Exp Immunol 160(2):283-292
44. Ding Q, Luckhardt T, Hecker L, Zhou Y, Liu G, Antony VB, de Andrade J, Thannickal VJ (2011) New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. Drugs 71(8):981-1001
45. Kinnula VL, Fattman CL, Tan RJ, Oury TD (2005) Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 172(4):417-422
46. Bast A, Weseler AR, Haenen GR, den Hartog GJ (2010) Oxidative stress and antioxidants in interstitial lung disease. Curr Opin Pulm Med 16(5):516-520
47. Qi S, den Hartog GJ, Bast A (2009) Superoxide radicals increase transforming growth factor-beta1 and collagen release from human lung fibroblasts via cellular influx through chloride channels. Toxicol Appl Pharmacol 237(1):111-118
48. Singal AK, Jampana SC, Weinman SA (2011) Antioxidants as therapeutic agents for liver disease. Liver Int 31(10):1432-1448
49. Denas G, Pengo V (2012) Current anticoagulant safety. Expert Opin Drug Saf 11(3):401-413
50. Costantino G, Ceriani E, Rusconi AM, Podda GM, Montano N, Duca P, Cattaneo M, Casazza G (2012) Bleeding risk during treatment of acute thrombotic events with subcutaneous LMWH compared to intravenous unfractionated heparin; a systematic review. PLoS One 7(9):e44553
51. Robert-Ebadi H, Le Gal G, Righini M (2009) Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging 4:165-177
52. Steffel J, Luscher TF (2012) Vitamin K antagonists. Ready to be replaced? Hamostaseologie 32(4):249-257
53. Masip J, Vecilla F, Paez J (1998) Diffuse pulmonary hemorrhage after fibrinolytic therapy for acute myocardial infarction. Int J Cardiol 63(1):95-97
54. Awadh N, Ronco JJ, Bernstein V, Gilks B, Wilcox P (1994) Spontaneous pulmonary hemorrhage after thrombolytic therapy for acute myocardial infarction. Chest 106(5):1622-1624